Suppression of EGFR-STAT3 signaling inhibits tumorigenesis in a lung cancer cell line

International Journal of Clinical and Experimental Medicine

Volumn 7, Issue 8, 2014, Pages 2096-2099

  Jiang, Yong Qian ^a   Zhou, Zhi Xiang ^a   Ji, You Lin ^a  

^a Department of Respiratory Medicine The First People s Hospital of Yancheng City   (China)

Author keywords

EGFR STAT3; Lung cancer; Signal transduction

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; NIMOTUZUMAB; STAT3 PROTEIN;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CELL CYCLE ASSAY; CELL DIVISION; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; FILTERS AND MEMBRANES; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LUNG CANCER; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

EID: 84907166917     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Prigent SA, Lemoine NR. The type 1 (EGFR-related) family of growth factor receptors and their ligands. Prog Growth Factor Res 1992; 4: 1-24.
2. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001; 37: 9-15.
3. Hoey T, Schindler U. STAT structure and function in signaling. Curr Opin Genet Dev 1998; 8: 582-587.
4. Giraud AS, Menheniott TR, Judd LM. Targeting STAT3 in gastric cancer. Expert Opin Ther Targets 2012; 16: 889-901.
5. Chan KS, Carbajal S, Kiguchi K, Clifford J, Sano S, Digiovanni J. Epidermal growth factor receptor-mediated activation of Stat3 during multistage skin carcinogenesis. Cancer Res 2004; 64: 2382-2389.
6. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW. Epidermal growth factor receptor: mechanisms of activation and signaling. Exp Cell Res 2003; 284: 31-53.
7. Juergens RA, Brahmer JR. Adjuvant treatment in non-small cell lung cancer: Where are we now? J Natl Compr Canc Netw 2006; 4: 595-600.
8. Brambilla E, Travis WD, Colby TV, Corrin B, Shimosato Y. The New World Health Organization Classification of lung tumors. Eur Respir J 2001; 18: 1059-1068.
9. Smith RA, Glynn TJ. Epidemiology of lung cancer. Radiol Clin North Am 2000; 38: 453-470.
10. Miller JD, Gorenstein LA, Patterson GA. Staging: the key to rational management of lung cancer. Ann Thorac Surg 1992; 53: 170-178.
11. Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, Kalman L, Miller V, Lee JS, Moore M, Gandara D, Karp D, Vokes E, Kris M, Kim Y, Gamza F, Hammershaimb L. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000; 18: 2354-2362.
12. Herrera B, van Dinther M, Ten DP, Inman GJ. Autocrine bonemorphogenetic protein-9 signals through activin receptor-likekinase-2/Smad1/Smad4 to promote ovarian cancer cell proliferation. Cancer Res 2009; 69: 9254-9262.
13. Scagliotti GV, Selvaggi G, Novello S, Hirsch FR. The biology of epidermal growth factor receptor in lung cancer. Clin Cancer Res 2004; 10: 4227-4232.
14. Ford AC, Grandis JR. Targeting epidermal growth factor receptor in head and neck cancer. Head Neek 2003; 25: 67-73.
15. Arteaga CL. Epidermal growth factor receptor dependence in human tumors: more than just expression? Onclogist 2002; 7: 31-39.
16. Jean GW, Shah SR. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer. Pharmacotherapy 2008; 28: 742-754.
17. Tiseo M, Loprevite M, Ardizzoni A. Epidermal growth factor receptor inhibitors: a new prospective in the treatment of lung cancer. Curr Med Chem Anticancer Agents 2004; 4: 139-148.